• 1
    Wong BCY, Ching CK, Lam SK, et al. Differential north to south gastric cancer – duodenal ulcer gradient in China. J Gastroenterol Hepatol 1998; 13: 10507.
  • 2
    Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 12735.
  • 3
    International Agency for Research on Cancer, World Health Organization. Infection with Helicobacter pylori, schistosomes, liver flukes and Helicobacter pylori, IARC, Lyon, 1994 Monogr. Eval Carcinog Risks Hum 1994; 60: 177240.
  • 4
    Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 659.
  • 5
    Li YY, Hu PJ, Du GG, Hazell SL. The prevalence of Helicobacter pylori infection in the Peoples Republic of China. Am J Gastroenterol 1991; 86: 4469.
  • 6
    Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 25763.
  • 7
    Xia HHX, Kalantar JS, Mitchell HM, Talley NJ. Can Helicobacter pylori serology still be a surrogate marker to identify peptic ulcer disease in dyspepsia? Aliment Pharmacol Ther 2000; 14: 61524.
  • 8
    Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal antiinflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 1992; 87: 1398402.
  • 9
    Henry D, Lim LLY, Garci̇’a Rodri̇’guez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 15636.
  • 10
    Luis AGR, Sonia HD. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004; 159: 2331.
  • 11
    Xia HHX, Wong BCY, Talley NJ, Lam SK. Helicobacter pylori infection – current treatment practice. Expert Opin Pharmacother 2001; 2: 25366.
  • 12
    Xia HHX, Wong BCY, Talley NJ, Lam SK. Alternative and rescue treatment regimens for Helicobacter pylori eradication. Expert Opin Pharmacother 2002; 3: 130111.
  • 13
    Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther 1995; 9(Suppl. 2): 312.
  • 14
    Xia HHX, Phung N, Altiparmak E, Berry A, Matheson M, Talley NJ. Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in western Sydney between 1990 and 1998. Dig Dis Sci 2001; 46: 271623.
  • 15
    Wong BCY, Wong KW, Chan CK, et al. Evaluation of a new referral system for the management of dyspepsia in Hong Kong: role of open access upper endoscopy. J Gastroenterol Hepatol 2000; 15: 12516.
    Direct Link:
  • 16
    Wong BCY, Xiao SD, Hu FL, et al. Comparison of lansoprazole-based triple therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. Aliment Pharmacol Ther 2000; 14: 21724.
  • 17
    Wong BCY, Wong WM, Wang WH, et al. An evaluation of invasive and non-invasive tests for the diagnosis of Helicobacter pylori infection in Chinese. Aliment Pharmacol Ther 2001; 15: 50511.
  • 18
    Xia HHX, Wong BCY, Wong KW, et al. Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective study. Aliment Pharmacol Ther 2001; 15: 187582.
  • 19
    Kearney DJ, Liu CF, Crump C, Brousal A. The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia. Am J Gastroenterol 2003; 98: 195262.
    Direct Link:
  • 20
    Matsukawa Y, Aoki M, Nishinarita S, et al. Prevalence of Helicobacter pylori in NSAID users with gastric ulcer. Rheumatology (Oxford) 2003; 42: 94750.
  • 21
    Nensey YM, Schubert TT, Bologna SD, Ma CK. Helicobacter pylori-negative duodenal ulcer. Am J Med 1991; 91: 158.
  • 22
    Borody TJ, George LL, Brandl S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991; 86: 11547.
  • 23
    Kemppainen H, Raiha I, Kujari H, Sourander L. Characteristics of Helicobacter pylori-negative and -positive peptic ulcer disease. Age Ageing 1998; 27: 42731.
  • 24
    Wang WH, Wong WM, Dailidiene D, et al. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 2003; 52: 4905.
  • 25
    Gu Q, Xia HHX, Wang WH, et al. Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. Aliment Pharmacol Ther 2004; 20: 67581.
  • 26
    Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 8: 12431.
  • 27
    Kuipers EJ, Malfertheiner P. Helicobacter pylori and nonmalignant diseases. Helicobacter 2004; 9(Suppl. 1): 2934.
  • 28
    Sung JJY. Should we eradicate Helicobacter pylori in non-steroidal anti-inflammatory drug users? Aliment Pharmacol Ther 2004; 20(Suppl. 2): 6570.
  • 29
    Lanas A. Prevention of aspirin-induced gastroduodenal damage: H. pylori infection eradication versus proton pump inhibitors or both. Dig Liver Dis 2004; 36: 6557.
  • 30
    Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003; 17: 799805.
  • 31
    Lai KC, Lam SK, Chu KM, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users – a randomized trial. Aliment Pharmacol Ther 2003; 18: 82936.
  • 32
    Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 18794.